Rationale for a phase III study of erythropoietin as a neurocognitive protectant in patients with lung cancer receiving prophylactic cranial irradiation

Seminars in Oncology

Volumn 29, Issue 6 SUPPL. 19, 2002, Pages 47-52

  Senzer, Neil ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; MESSENGER RNA; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; BRAIN METASTASIS; CANCER PREVENTION; CANCER SURVIVAL; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONFERENCE PAPER; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; META ANALYSIS; MULTIMODALITY CANCER THERAPY; NERVE CELL; NEUROLOGICAL COMPLICATION; NEUROTOXICITY; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION PROTECTION; SKULL IRRADIATION; TARGET ORGAN; TASK PERFORMANCE;

ANIMALS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CELL HYPOXIA; CLINICAL TRIALS, PHASE III; COGNITION; CRANIAL IRRADIATION; CYTOPROTECTION; DRUG EVALUATION, PRECLINICAL; ERYTHROPOIETIN; HUMANS; LUNG NEOPLASMS; NEUROPROTECTIVE AGENTS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 0036981235     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.37362     Document Type: Conference Paper

References (43)

1. Auperin A, Arriagada R, Pignon JP, et al: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 341:476-484, 1999
2. Carney DN: Prophylactic cranial irradiation and small-cell lung cancer. N Engl J Med 341:524-526,1999
3. Albain KS, Rusch VW, Crowley JJ, et al: Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13:1880-1892, 1995
4. Albain KS, Crowley JJ, Turrisi AT III, et al: Concurrent cisplatin/etoposide plus radiotherapy (PE+RT) for pathologic stage IIIB non-small cell lung cancer: A Southwest Oncology Group phase II study (S9019). Proc Am Soc Clin Oncol 16:446a, 1997 (abstr 1600)
5. Gaspar L, Gandara D, Chansky K, et al: Consolidation docetaxel following concurrent chemoradiotherapy in pathologic stage IIIB non-small cell lung cancer (NSCLC) (SWOG 9504): Patterns of failure and updated survival. Proc Am Soc Clin Oncol 20:315a, 2001 (abstr 1255)
6. Law A, Karp DD, Dipetrillo T, et al: Emergence of increased cerebral metastasis after high-dose preoperative radiotherapy with chemotherapy in patients with locally advanced non small cell lung cancer. Cancer 92:160-164, 2001
7. Stuschke M, Eberhardt W, Pottgen C, et al: Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: Long-term follow-up and investigations of late neuropsychologic effects. J Clin Oncol 17:2700-2709, 1999
8. Ball DL, Matthews JP: Prophylactic cranial irradiation: More questions than answers. Semin Radiat Oncol 5:61-68, 1995
9. Van Oosterhout A, Boon PJ, Houx PJ, et al: Follow-up of cognitive functioning in patients with small cell lung cancer. Int J Radiat Oncol Biol Phys 31:911-914, 1995
10. Komacki R, Meyers CA, Shin DM, et al: Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Inr J Radiat Oncol Biol Phys 33:179-182, 1995
11. Ahles TA, Silberfarb PM, Herdon J, et al: Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: A study by the Cancer and Leukemia Group Br J Clin Oncol 16:1954-1960, 1998
12. Levy AP, Levey NS, Wegner S, et al: Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 270:13333-13340, 1995
13. Digicaylioglu M, Bichet S, Marti HH, et al: Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci U S A 92:3717-3220, 1995
14. Masuda S, Okano M, Yamagishi K, et al: A novel site of erythropoietin production. J Biol Chem 269:19488-19493, 1994
15. Bernaudin M, Bellail A, Marti HH, et al: Neurons and astrocytes express EPO mRNA: Oxygen-sensing mechanisms that involve the redox-state of the brain. Glia 30:271-278, 2000
16. Morishita E, Masuda S, Nagao M, et al: Erythropoietin receptor is expressed in rat hippocampal and cerebral neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 76:105-116, 1997
17. 2-induced neuronal apoptosis. J Neurochem 73:1181-1188, 1999
18. Cheng B, Mattson MP: PDGFs protect hippocampal neurons against energy deprivation and oxidative injury: Evidence for induction of antioxidant pathways. J Neurosci 15:7095-7104, 1995
19. Sakanaka M, Wen TC, Matsuda S, et al: In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A 95:4635-4640, 1998
20. Leach JK, Tuyle GV, Lin PS, et al: Ionizing radiation- induced, mitochondria-dependent generation of reactive oxygen/nitrogen. Cancer Res 61:3894-3901, 2001
21. Ghafourifar P, Schenk U, Klein SD, et al: Mitochondrial nitric-oxide synthase stimulation causes cytochrome c release from isolated mitochondria. J Biol Chem 274:31185-31188, 1999
22. Beckman JS, Beckman TW, Chen J, et al: Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 87:1620-1624, 1990
23. Calapai G, Marciano MC, Corica F, et al: Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur J Pharmacol 401:349-356, 2000
24. Dubinsky JM, Kristal BS, Elizondo-Fournier M: An obligate role for oxygen in the early stages of glutamate-induced, delayed neuronal death. J Neurosci 15:7071-7078, 1995
25. Duranteau J, Chandel NS, Kulisz A, et al: Intracellular signaling by reactive oxygen species during hypoxia in cardiomyocytes. J Biol Chem 273:11619-11624, 1998
26. Chandel NS, Maltepe E, Goldwasser E, et al: Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci U S A 95:11715-11720, 1998
27. Masakatsu M, Sekiguchi M, Sato K, et al: Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J Biol Chem 276:39469-39475, 2001
28. Siren AL, Fratelli M, Brines M, et al: Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 98:4044-4049, 2001
29. Digicaylioglu M, Lipton SA: Erythopoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signalling cascades. Nature 412:641-647, 2001
30. Shaulian E, Karin M: AP-1 as a regulator of cell life and death. Nature Cell Biol 4:E131-E136, 2002
31. Whitfield J, Neame SJ, Paquet L, et al: Dominant-negative c-jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome-c release. Neuron 29:629-643, 2001
32. Brines ML, Ghezzi P, Keenan S, et al: Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97:10526-10531, 2000
33. Hengemihle JM, Abugo O: Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice. Physiol Behav 59:153-156, 1996
34. Catania MA, Marciano MC, Parisi A, et al: Erythropoietin prevents cognition impairment induced by transient brain ischemia in gerbils. Eur J Pharmacol 437:147-150, 2002
35. O'Shaughnessy J, Vukelja S, Savin, et al: Effects of epoetin alfa (Procrit) on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy: A double-blind, randomized, placebo-controlled study. Proc Am Soc Clin Oncol 21:363a, 2002 (abstr)
36. Benedict RHB, Schretlen D, Groninger L, et al: Hopkins Verbal Learning Test-Revised: Normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol 12:43-55, 1998
37. Brandt J: The Hopkins Verbal Learning Test: Development of a new memory test with six equivalent forms. Clin Neuropsychol 5:125-142, 1991
38. Rasmusson DX, Bylsma FW, Brandt J: Stability of performance on the Hopkins Verbal Learning Test-Revised. Clin Neuropsychol 10:21-26, 1995
39. Shapiro AM, Benedict RHB, Schretlen D, et al: Construct and concurrent validity of the Hopkins Verbal Learning Test-Revised. Clin Neuropsychol 13:348-358, 1999
40. Reitan RM: The relation of the Trail Making Test to organic brain damage. J Consul Clin Psychol 19:193-194, 1995
41. Reitan RM: The validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 8:127- 130, 1958
42. Royall DR, Mulroy AR, Chiodo LK, et al: Clock drawing is sensitive to executive control: A comparison of six methods. J Gerontol B Psychol Sci Soc Sci 54P:328-333, 1999
43. Royall DR, Cordes JA, Polk M: CLOX: An executive clock drawing task. J Neurol Neurosurg Psychiatry 64:588-594, 1998